Vertex Pharmaceuticals Incorporated — Company profile
Healthcare · Biotechnology · United States
Last price 558.88 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 141.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Details
| Name | Vertex Pharmaceuticals Incorporated |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 6400 |
| Founded | 1989 |
| Ipo Date | 1991-07-24 |
| Ceo | Reshma Kewalramani |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US92532F1003 |
| Cusip | 92532F100 |
| Cik | 0000875320 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Reshma Kewalramani FASN, M.D. | Chief Executive Officer, President and Director |
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman |
| Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
| Amit K. Sachdev J.D. | Executive Vice President and Chief Patient and External Affairs Officer |
| Dr. Ourania Tatsis Ph.D. | Executive Vice President and Chief Product Affairs Officer |
| Dr. Carmen Bozic M.D. | Executive Vice President of Global Medicines Development and Medical Affairs and Chief Medical Officer |
| Kristen C. Ambrose CPA | Senior Vice President and Chief Accounting Officer |
| Dr. Mark Bunnage D.Phil | Executive Vice President and Chief Scientific Officer |
| Susie Lisa C.F.A. | Senior Vice President of Investor Relations |
| Joy Liu J.D. | EVice President, Chief Legal Officer and Corporate Secretary |
Contact
| Address | 50 Northern Avenue, Boston, Massachusetts 02210, United States |
| Phone | 617 341 6100 |
| Website | https://www.vrtx.com |